GlassScriptPhysician profile
Donald E Mason
NPI 1710132246
$2,230.82
in general payments reported to CMS, 2019-2025
31 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $708 · 2023: $648 · 2024: $533 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.36 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $161.33 | 2022-2023 | Breztri, Farxiga |
| Vanda Pharmaceuticals INC. | $133.13 | 2022-2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $129.27 | 2022-2023 | Mounjaro, Jardiance |
| Nestle Healthcare Nutrition INC. | $122.65 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.39 | 2022-2023 | Jardiance |
| Lundbeck LLC | $84.26 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $82.30 | 2024-2025 | Abilify Mycite, Abilify Maintena, Rexulti |
| Novo Nordisk INC | $74.16 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.99 | 2022-2023 | Xifaxan |
| Alkermes, INC. | $62.84 | 2024-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $54.96 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.05 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $47.80 | 2022-2023 | Shingrix, Arexvy |
| Sanofi Pasteur INC. | $45.32 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $41.37 | 2023-2024 | Nalu Neurostimulation System |
| Pfizer INC. | $36.10 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $26.56 | 2022-2023 | Contrave, Onzetra Xsail |
| Baxter Healthcare | $24.89 | 2022 | |
| Abbott Laboratories | $23.17 | 2022 | |
| Gilead Sciences, INC. | $23.16 | 2022 | |
| Boston Scientific Corporation | $19.30 | 2023 | Watchman Flx |
| Teleflex LLC | $16.93 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.76 | 2022 | |
| Medtronic, INC. | $16.72 | 2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $16.33 | 2022 | |
| Si-Bone, INC. | $16.15 | 2022 | |
| Hologic Sales and Service, LLC | $15.46 | 2022 | |
| Amgen INC. | $14.86 | 2023 | Evenity, Prolia |
| Insulet Corporation | $14.34 | 2023 | Omnipod |
| Azurity Pharmaceuticals, INC. | $12.91 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.